Geoffrey Porges
Stock Analyst at SVB Leerink
(1.38)
# 3,190
Out of 4,829 analysts
132
Total ratings
42.35%
Success rate
-6.96%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Geoffrey Porges
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PFE Pfizer | Maintains: Market Perform | $52 → $56 | $23.09 | +142.53% | 10 | Dec 15, 2021 | |
| RDUS Radius Recycling | Maintains: Market Perform | $30 → $20 | $29.38 | -31.93% | 10 | Dec 9, 2021 | |
| RCUS Arcus Biosciences | Maintains: Outperform | $68 → $100 | $8.80 | +1,036.36% | 8 | Nov 18, 2021 | |
| REGN Regeneron Pharmaceuticals | Maintains: Outperform | $798 → $850 | $575.63 | +47.66% | 16 | Nov 5, 2021 | |
| HALO Halozyme Therapeutics | Maintains: Outperform | $50 → $48 | $66.58 | -27.91% | 2 | Nov 3, 2021 | |
| AMGN Amgen | Maintains: Market Perform | $234 → $216 | $274.76 | -21.39% | 12 | Nov 3, 2021 | |
| ABBV AbbVie | Maintains: Outperform | $142 → $135 | $190.07 | -28.97% | 16 | Nov 1, 2021 | |
| ROIV Roivant Sciences | Initiates: Outperform | $11 | $10.99 | +0.09% | 1 | Nov 1, 2021 | |
| GILD Gilead Sciences | Maintains: Outperform | $77 → $75 | $103.82 | -27.76% | 14 | Oct 29, 2021 | |
| SNY Sanofi | Upgrades: Outperform | n/a | $51.06 | - | 2 | Sep 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $29 → $10 | $8.80 | +13.64% | 9 | Sep 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $35 → $30 | $0.31 | +9,723.18% | 8 | Aug 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $170 → $175 | $439.37 | -60.17% | 9 | Jul 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $96 → $84 | $12.35 | +580.16% | 3 | May 10, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $37.37 | - | 1 | Mar 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $33 | $3.41 | +867.74% | 1 | Nov 11, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $61 | $6.60 | +824.24% | 2 | Nov 28, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $124.40 | - | 8 | Mar 16, 2017 |
Pfizer
Dec 15, 2021
Maintains: Market Perform
Price Target: $52 → $56
Current: $23.09
Upside: +142.53%
Radius Recycling
Dec 9, 2021
Maintains: Market Perform
Price Target: $30 → $20
Current: $29.38
Upside: -31.93%
Arcus Biosciences
Nov 18, 2021
Maintains: Outperform
Price Target: $68 → $100
Current: $8.80
Upside: +1,036.36%
Regeneron Pharmaceuticals
Nov 5, 2021
Maintains: Outperform
Price Target: $798 → $850
Current: $575.63
Upside: +47.66%
Halozyme Therapeutics
Nov 3, 2021
Maintains: Outperform
Price Target: $50 → $48
Current: $66.58
Upside: -27.91%
Amgen
Nov 3, 2021
Maintains: Market Perform
Price Target: $234 → $216
Current: $274.76
Upside: -21.39%
AbbVie
Nov 1, 2021
Maintains: Outperform
Price Target: $142 → $135
Current: $190.07
Upside: -28.97%
Roivant Sciences
Nov 1, 2021
Initiates: Outperform
Price Target: $11
Current: $10.99
Upside: +0.09%
Gilead Sciences
Oct 29, 2021
Maintains: Outperform
Price Target: $77 → $75
Current: $103.82
Upside: -27.76%
Sanofi
Sep 27, 2021
Upgrades: Outperform
Price Target: n/a
Current: $51.06
Upside: -
Sep 16, 2021
Maintains: Outperform
Price Target: $29 → $10
Current: $8.80
Upside: +13.64%
Aug 10, 2021
Maintains: Outperform
Price Target: $35 → $30
Current: $0.31
Upside: +9,723.18%
Jul 30, 2021
Maintains: Underperform
Price Target: $170 → $175
Current: $439.37
Upside: -60.17%
May 10, 2021
Maintains: Market Perform
Price Target: $96 → $84
Current: $12.35
Upside: +580.16%
Mar 23, 2021
Downgrades: Market Perform
Price Target: n/a
Current: $37.37
Upside: -
Nov 11, 2020
Initiates: Outperform
Price Target: $33
Current: $3.41
Upside: +867.74%
Nov 28, 2018
Initiates: Outperform
Price Target: $61
Current: $6.60
Upside: +824.24%
Mar 16, 2017
Downgrades: Market Perform
Price Target: n/a
Current: $124.40
Upside: -